Teng-Le Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Teng-Le Huang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Chia-Jou Wang
Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
1 shared publication - Chia-Yang Chen
Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
1 shared publication - Chu-Han Chang
Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
1 shared publication - Chun-Hao Tsai
Department of Orthopedic Surgery, China Medical University Hospital, China Medical University, Taichung, Taiwan
1 shared publication - Hung-Lun Hsieh
Department of Orthopedic Surgery, China Medical University Beigang Hospital, China Medical University, Yunlin, Taiwan
1 shared publication - Tsung-Ming Chen
Department and Graduate Institute of Aquaculture, National Kaohsiung University of Science and Technology, Kaohsiung, Taiwan
1 shared publication
Latest Publications
- Open Access
- 3 June 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 15 (6) , 632-646
FGF9 attenuates osteoarthritis progression through the NRF2/GPX3 antioxidant axis
Aims: Osteoarthritis (OA), a prevalent age-related joint disease affecting over 250 million people globally, currently lacks effective disease-modifying treatments. Fibroblast growth factor 9 (FGF9) has shown cartilage-protective effects in post-traumatic OA models, but its role in chondrocyte degeneration and OA pathogenesis remains unclear. This study investigates FGF9’s function in human and murine chondrocytes and its therapeutic potential for OA. Methods: Gene expression profiling was performed on primary chondrocytes from OA patients and normal controls. Senescence and reactive oxygen species (ROS) levels were assessed by β-galactosidase staining and flow cytometry. FGF9 function was evaluated through short hairpin RNA (shRNA)-mediated knockdown and treatment with FGF9-conditioned media (CM). The impact of FGF9-enriched exosomes on chondrocyte senescence was also examined in vitro. In vivo effects were tested using adenovirus-delivered FGF9 in a destabilization of the medial meniscus (DMM)-induced OA mouse model. Results: FGF9 expression was significantly downregulated in OA chondrocytes (n = 195) compared to normal (n = 71). FGF9 knockdown elevated ROS levels and senescence via suppression of the NRF2/GPX3 antioxidant axis, while FGF9 promoted chondrogenesis in mesenchymal stem cells. Intra-articular FGF9 gene therapy reduced OA progression in DMM mice. Additionally, FGF9-enriched exosomes reduced senescence in primary chondrocytes in vitro. Conclusion: FGF9 alleviates OA progression by activating the NRF2/GPX3 pathway, reducing ROS and chondrocyte senescence. These findings support the therapeutic potential of FGF9 and FGF9-enriched exosomes in OA treatment. Cite this article: Bone Joint Res 2026;15(6):632–646.
- 3 June 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 15 (6) , 632-646
Open AccessFGF9 attenuates osteoarthritis progression through the NRF2/GPX3 antioxidant axis
Aims: Osteoarthritis (OA), a prevalent age-related joint disease affecting over 250 million people globally, currently lacks effective disease-modifying treatments. Fibroblast growth factor 9 (FGF9) has shown cartilage-protective effects in post-traumatic OA models, but its role in chondrocyte degeneration and OA pathogenesis remains unclear. This study investigates FGF9’s function in human and murine chondrocytes and its therapeutic potential for OA. Methods: Gene expression profiling was performed on primary chondrocytes from OA patients and normal controls. Senescence and reactive oxygen species (ROS) levels were assessed by β-galactosidase staining and flow cytometry. FGF9 function was evaluated through short hairpin RNA (shRNA)-mediated knockdown and treatment with FGF9-conditioned media (CM). The impact of FGF9-enriched exosomes on chondrocyte senescence was also examined in vitro. In vivo effects were tested using adenovirus-delivered FGF9 in a destabilization of the medial meniscus (DMM)-induced OA mouse model. Results: FGF9 expression was significantly downregulated in OA chondrocytes (n = 195) compared to normal (n = 71). FGF9 knockdown elevated ROS levels and senescence via suppression of the NRF2/GPX3 antioxidant axis, while FGF9 promoted chondrogenesis in mesenchymal stem cells. Intra-articular FGF9 gene therapy reduced OA progression in DMM mice. Additionally, FGF9-enriched exosomes reduced senescence in primary chondrocytes in vitro. Conclusion: FGF9 alleviates OA progression by activating the NRF2/GPX3 pathway, reducing ROS and chondrocyte senescence. These findings support the therapeutic potential of FGF9 and FGF9-enriched exosomes in OA treatment. Cite this article: Bone Joint Res 2026;15(6):632–646.